BioMarin Pharmaceutical Balance Sheet Health
Financial Health criteria checks 6/6
BioMarin Pharmaceutical has a total shareholder equity of $5.1B and total debt of $1.1B, which brings its debt-to-equity ratio to 21.4%. Its total assets and total liabilities are $6.9B and $1.8B respectively. BioMarin Pharmaceutical's EBIT is $189.5M making its interest coverage ratio -3.9. It has cash and short-term investments of $1.0B.
Key information
21.4%
Debt to equity ratio
US$1.09b
Debt
| Interest coverage ratio | -3.9x |
| Cash | US$1.05b |
| Equity | US$5.07b |
| Total liabilities | US$1.80b |
| Total assets | US$6.87b |
Recent financial health updates
Is BioMarin Pharmaceutical (NASDAQ:BMRN) Using Too Much Debt?
Mar 30
Is BioMarin Pharmaceutical (NASDAQ:BMRN) Using Too Much Debt?
Nov 03We Think BioMarin Pharmaceutical (NASDAQ:BMRN) Can Stay On Top Of Its Debt
Jul 18These 4 Measures Indicate That BioMarin Pharmaceutical (NASDAQ:BMRN) Is Using Debt Safely
Mar 27Would BioMarin Pharmaceutical (NASDAQ:BMRN) Be Better Off With Less Debt?
May 25BioMarin Pharmaceutical (NASDAQ:BMRN) Has Debt But No Earnings; Should You Worry?
Feb 24Recent updates
Results: BioMarin Pharmaceutical Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates
Apr 26BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) Shares Lagging The Industry But So Is The Business
Apr 21Is BioMarin Pharmaceutical (NASDAQ:BMRN) Using Too Much Debt?
Mar 30BioMarin Pharmaceutical: Still Has A Lot Of Room For Growth
Feb 29BioMarin's Growth Potential And Valuation: Is Now The Right Time To Invest?
Jan 19Little Excitement Around BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) Revenues
Jan 05Is BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Trading At A 49% Discount?
Dec 15Is BioMarin Pharmaceutical (NASDAQ:BMRN) Using Too Much Debt?
Nov 03Is BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Trading At A 42% Discount?
Aug 09We Think BioMarin Pharmaceutical (NASDAQ:BMRN) Can Stay On Top Of Its Debt
Jul 18BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Shares Could Be 42% Below Their Intrinsic Value Estimate
May 09Why Investors Shouldn't Be Surprised By BioMarin Pharmaceutical Inc.'s (NASDAQ:BMRN) Low P/S
Apr 18These 4 Measures Indicate That BioMarin Pharmaceutical (NASDAQ:BMRN) Is Using Debt Safely
Mar 27An Intrinsic Calculation For BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Suggests It's 39% Undervalued
Jan 09BioMarin redesigns organization, will lay off about 4% of its workforce
Oct 07BioMarin resubmits biologics license application to FDA for hemophilia A gene therapy
Sep 29BioMarin touts report on cost effectiveness of gene therapy Roctavian for hemophilia A
Sep 15BioMarin to resubmit hemophilia therapy for FDA approval after EU nod
Aug 25BioMarin may be an activist target after 13-F filings
Aug 15BioMarin (BMRN) boosts 2022 top and bottom line guidance on back of product sales growth
Aug 03BioMarin: More Growth
Jul 21BioMarin's Solid Pipeline Bears The First Fruit
Jun 27Would BioMarin Pharmaceutical (NASDAQ:BMRN) Be Better Off With Less Debt?
May 25BioMarin: A Good Anchor For Your Biotech Portfolio
May 10BioMarin: Keep Waiting For The Growth
Mar 03BioMarin Pharmaceutical (NASDAQ:BMRN) Has Debt But No Earnings; Should You Worry?
Feb 24Financial Position Analysis
Short Term Liabilities: BMRN's short term assets ($3.0B) exceed its short term liabilities ($1.1B).
Long Term Liabilities: BMRN's short term assets ($3.0B) exceed its long term liabilities ($711.0M).
Debt to Equity History and Analysis
Debt Level: BMRN's net debt to equity ratio (0.8%) is considered satisfactory.
Reducing Debt: BMRN's debt to equity ratio has reduced from 28.4% to 21.4% over the past 5 years.
Debt Coverage: BMRN's debt is well covered by operating cash flow (25.8%).
Interest Coverage: BMRN earns more interest than it pays, so coverage of interest payments is not a concern.